DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Bethesda North Marriott Hotel and Conference Center

2018 年 04 月 24 日 7:00 上午 - 2018 年 04 月 25 日 3:00 下午

5701 Marinelli Road, , North Bethesda, MD 20852 , USA

Global Labeling Conference

Session 1: Updated Global Regulations and Guidances (Including Canada and Australia)

Session Chair(s)

Mark  Collins, PhD, MBA

Mark Collins, PhD, MBA

Principal Consultant

Opus Regulatory, United States

This session reviews recent updates to global regulations and guidances and the update on the Structured Product Monograph (SPM) initiative in Canada. A representative from Health Canada has been invited and the session also contains an industry viewpoint.

Learning Objective : At the conclusion of this session, participants should be able to:
  • Describe the recent changes to the Australian Product Information Template
  • Describe the criteria for adding adverse reactions to the labeling in the major markets and to reference safety information (RSI) in clinical trial applications in the EU
  • Discuss the current SPM Initiative in Canada

Speaker(s)

Mark  Collins, PhD, MBA

Recent Changes to the Product Information Requirements in Australia and New Zealand

Mark Collins, PhD, MBA

Opus Regulatory, United States

Principal Consultant

A. Leander  Fontaine, MD

Adverse Reactions in Regional Labeling and Investigator Brochures: Inconsistent Expectations

A. Leander Fontaine, MD

Pharmiceutics, LLC., United States

President

Craig  Anderson

The Canadian Structured Product Monograph (SPM) Initiative

Craig Anderson

Pfizer Inc , Canada

Director, R&D Labeling Lead, International Labeling

Luiza  Madeira

The Canadian Structured Product Monograph (SPM) Initiative from an Industry Perspective

Luiza Madeira

Eli Lilly Canada Inc., Canada

Consultant, Global Labeling Department

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。